Why delaying levodopa is a good treatment strategy in early Parkinson's disease

European Journal of Neurology

Volumn 7, Issue , 2000, Pages 3-8

  Olanow, C W ^a   Stocchi, F ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine agonists; Levodopa; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AEROBIC METABOLISM; CONFERENCE PAPER; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0034464115     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2000.0070s1006.x     Document Type: Article

References (53)

1. 3H]spiperone binding
2. 2 agonist (U-91356A) in MPTP monkeys
3. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine
4. 2 receptor agonist, decreases the extracellular concentration of dopamine in vivo
5. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
6. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
7. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part I
8. Adverse effects of Levodopa
9. Behavioral and biochemical effect of chronic treatment with D1 and/or D2 dopamine agonists in MPTP monkeys
10. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats
11. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
12. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists
13. Dopamine function in the striatum: Implications for dopamine receptor agonist treatment of Parkinson's disease
14. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurones
15. 2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naïve primates
16. Long term administration of L-dopa does not damage dopaminergic neurons in the mouse
17. Pramipexole versus levodopa in early Parkinson's disease: A randomized clinical trial
18. Understanding cell death in Parkinson's disease
19. Continuous and intermittent levodopa differentially affect basal ganglia function
20. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
21. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture
22. A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: A 3 year follow-up
23. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow up
24. Toxic and protective effects of L-dopa on mesencephalic cell cultures
25. The response to levodopa in Parkinson's disease: Imposing pharmacologic law and order
26. The on-off phenomenon in Parkinson's disease: Relation to levodopa absorption and transport
27. Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine
28. Bromocripfine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro
29. Oxidation reactions in Parkinson's disease
30. A rationale for dopamine agonists as primary therapy for Parkinson's disease
31. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease
32. A randomized blinded study of low dose Bromocriptine versus low dose Carbidopa/Levodopa in untreated Parkinson patients
33. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease
34. Preventing levodopa-induced dyskenesia
35. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for COMT inhibitors
36. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug naïve MPTP-treated common marmosets
37. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically
38. Functional roles for dopamine-receptor subtypes
39. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity
40. Preservation of the substantia nigra and locus coeruleus in patients receiving levodopa (2 gm) plus decarboxylase inhibitor over a four year period
41. A double blind L-DOPA controlled study of ropinirole in de novo patients with early Parkinson's disease
42. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
43. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5 year follow-up
44. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
45. Intense oxidative DNA damage promoted by L-DOPA and its metabolites: Implications for neurodegenerative disease
46. L-DOPA increases nigral production of hydroxyl radicals in vivo: Potential L-DOPA toxicity?
47. Dopamine turnover and glutathione oxidation: Implications for Parkinson's disease
48. Dopa and dopamine cause cultured neuronal death in the presence of iron
49. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by DOPA and iron
50. Induction of apoptosis in catecholaminergic PC 12 cells by L-DOPA. Implications for the treatment of Parkinson's disease
51. Antioxidant properties of bromocriptine, a dopamine agonist
52. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - A possible novel pathogenetic mechanism in Parkinson's disease